alexa Erythropoietin Ameliorates Experimental Autoimmune Myasthenia Gravis | OMICS International| Abstract

Journal of Clinical & Experimental Neuroimmunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Clin Exp Neuroimmunol 2016:108,

Erythropoietin Ameliorates Experimental Autoimmune Myasthenia Gravis

Debby Reuveni1,2, Smadar Gertel-Lapter1,2,3*, Revital Aricha1, Moshe Mittleman3,4, Sara Fuchs1, Drorit Neumann5 and Miriam C Souroujon1,2
1Department of Immunology, the Weizmann Institute of Science, , Rehovot, Israel
2Department of Sciences, the Open University of Israel, , Raanana, Israel
3Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
4Department of Medicine A, Tel-Aviv Sourasky Medical Center, , Israel
5Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Israel
*Corresponding Author : Smadar Gertel-Lapter, the Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Tel-Hashomer 5262100, Israel, Tel: 972-52-4543949, 972-3-5304985, Email: [email protected]

Received Date: Aug 30, 2015 / Accepted Date: Sep 30, 2016 / Published Date: Oct 05, 2016

Abstract

Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles. Erythropoietin (EPO) is a cytokine required to maintain erythroid cells. Recombinant human EPO
(rHuEPO) was found to act also on immune cells. Beneficial effects of rHuEPO therapy have been demonstrated in several experimental autoimmune models.

We have tested the effect of rHuEPO on the course of experimental autoimmune MG (EAMG) when treatment was initiated either at the acute or at the chronic phase of the disease. A significant ameliorating effect on the course of EAMG was achieved when the treatment started at the acute phase of EAMG, which was accompanied by elevated numbers of Treg. In addition, rHuEPO reduced the levels of anti-acetylcholine receptor (AChR) antibodies.

Our findings suggest that rHuEPO interferes in the course and progression of EAMG and may thus open new clinical opportunities for its use for immunomodulation of MG.

Keywords: Erythropoietin; Myasthenia Gravis; Autoimmune disorders

Citation: Reuveni D, Gertel-Lapter S, Aricha R, Mittleman M, Fuchs S, et al. (2016) Erythropoietin Ameliorates Experimental Autoimmune Myasthenia Gravis. J Clin Exp Neuroimmunol 1:108.

Copyright: ©2016 Reuveni D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 9818
  • [From(publication date): 10-2016 - Oct 29, 2020]
  • Breakdown by view type
  • HTML page views: 9635
  • PDF downloads: 183
Top